GLP-3 RT (Reta) 5–100mg
5 / 10 / 15 / 20 / 30 / 100 mg · Lyophilized
VaultLabs
Research peptides UAE
Loading page content…
Lot-tracked research materials, AED catalogue prices, and Dubai dispatch. The catalogue and product pages follow this screen.
VaultLabs
Research peptides UAE
Loading page content…
Lot-tracked research materials, AED catalogue prices, and Dubai dispatch. The catalogue and product pages follow this screen.
Featured research material selections combining popular peptides and support supplies for streamlined laboratory ordering. All materials are for in vitro research use only.
5 / 10 / 15 / 20 / 30 / 100 mg · Lyophilized
15 mg blend · Lyophilized
3 / 10 ml · Liquid
80 mg blend · Lyophilized
70 mg blend · Lyophilized
5 / 10 mg · Lyophilized
50 / 100 mg · Lyophilized
10 / 20 mg · Lyophilized
30 mg · Lyophilized
30 mg · Lyophilized
5 mg + 5 mg · Lyophilized
1000 mg · Lyophilized
1 g / 20 g · Raw powder
10 mg · Lyophilized
5 / 10 mg · Lyophilized
10 mg · Lyophilized
1500 mg · Lyophilized
100 mcg · Lyophilized
5 mg · Lyophilized
5 mg · Lyophilized
10 / 20 mg · Lyophilized
10 / 20 / 40 mg · Lyophilized
10 mg · Lyophilized
10 mg · Lyophilized
10 mg blend · Lyophilized
10 mg · Lyophilized
5 mg · Lyophilized
10 mg blend · Lyophilized
The first kind is a fixed-ratio blend released as a single vial. KLOW 80 mg combines BPC-157, GHK-Cu, TB-500 and KPV; GLOW 70 mg carries the first three of those and no KPV; Wolverine 10 mg is BPC-157 with TB-500; RETA/CAG 15 mg is retatrutide with cagrilintide; CJC-1295 without DAC is paired with ipamorelin. The second kind is the most frequently ordered single-compound vials, which appear here because of order volume rather than because they are packaged together — each remains its own SKU with its own lot.
Similar names are not evidence of equivalence, and this is where ordering errors concentrate. GLOW and KLOW differ by one component, are filled as different products, and share no documentation. RETA/CAG is a two-compound blend and not a dual-strength presentation of GLP-3 RT. A side-by-side comparison is more reliable than reasoning from the name, particularly when a protocol was written against one of them and a substitution is being considered.
Combining components into one vial creates a new manufacturing unit. It is filled, lyophilised and sealed as a single event, so it receives one lot number and one certificate describing that vial's contents. That record cannot be reconstructed from the component certificates: the ratio as filled, the fill accuracy, and how the mixture behaves under a single analytical method are properties of the blend rather than of its ingredients. VaultLabs therefore does not publish component certificates as blend documentation, and a component record should never be accepted as one.
There is an analytical consequence for whoever reads the paperwork. A blend chromatogram has to resolve several sequences in one run, so the method differs from a single-compound assay and area percentages are read per component rather than collapsed into one purity figure. Knowing which document you are holding matters more here than anywhere else in the catalogue — how to read a Certificate of Analysis covers the distinction. Where analytical release for a blend lot is complete, the record is published and matches the vial label, with the document type labelled on the record itself.
Separate vials give independent control and an independent record for each material. A component can be substituted, its lot changed, or dropped entirely, and the documentation still describes what was actually used. A blend gives a fixed ratio, one lot number to cite, and one storage and handling chain instead of three or four. Neither approach is better in the abstract; they answer different questions. If the design needs to vary one component while holding the others constant, buy components. If it needs the same combination reproduced across runs under one traceable record, the blend is the shorter path to defensible paperwork.
A move in either direction is a material change rather than a purchasing preference. Switching from components to a blend, or back, changes the lot chain, so previous records cannot be carried forward against the new material and a method reference should name the presentation explicitly. Before a blend lot enters an experiment, confirm the record against the label through COA verification; a blend that has been ordered several times still arrives as a different lot each time.